Indication

In combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2644
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
08 July 2024
SMC meeting date:
04 June 2024
Patient group submission deadline:
TBC